The Filing Desk

Ionis Pharmaceuticals

IONS · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

IONS · Last close · November 19, 2026
$27.22
Value Ionis Pharmaceuticals yourself

Ionis Pharmaceuticals' revenue rose 33.8% to $944 million in fiscal 2025. Its operating margin was −40.5%, up from −67.4% a year earlier. Free cash flow was −$320 million. The diluted share count rose 7.0%.

IONIS PHARMACEUTICALS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0000874015-26-000115 Updated
Revenue
$944M
33.8%
Operating margin
−40.5%
26.9 pts
Net income
−$381M
 
Free cash flow
−$320M
 
Return on equity
−70.8%
22.3 pts
Market cap
$4.5B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2017 to 2019, earnings per share grew 255.9% a year and net income 2,944.7% a year, as new shares raised the share count by 21% and diluted each share's earnings. Ionis Pharmaceuticals then lost money in fiscal 2020, 2021, 2022, 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments2,1151,9872,3312,2982,677
Debt incl. finance leases—1,1941,3081,2531,812
Net debt (negative means net cash)—−793−1,023−1,045−865
Net debt to EBITDA—————
Debt to equity—2.1x3.4x2.1x3.7x
Interest coverage−3.2x−50.5x−27.9x−28.0x−22.1x
Current ratio9.8x7.1x5.9x8.5x3.8x
Quick ratio9.7x7.0x5.9x8.4x3.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Ionis Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Ionis Pharmaceuticals says to expect

  • Full year 2026: DAWNZERA product salesOn track to achieve full year 2026 product sales guidance of $110-120 million, representing a continuing driver of year-over-year revenue growth
  • Full year 2026: TRYNGOLZA product salesFull year 2026 product sales guidance lowered to approximately $50 million, reflecting a more gradual launch ramp than anticipated as Ionis establishes a new treatment paradigm for people with sHTG
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $1.1 million of Ionis Pharmaceuticals shares on the open market, and 17 insiders sold $117.5 million, $98.4 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 31, 2026Michael R HaydenDirectorBought5,000$51.60$258,000Form 4
Jul 30, 2026Michael R HaydenDirectorBought15,000$53.38$800,700Form 4
Jul 7, 2026Bennett C FrankEVP, Chief Scientific OfficerSold plan20,536$84.95$1.7 millionForm 4
Jul 7, 2026Allene M. DiazDirectorSold plan10,111$85.42$863,682Form 4
Jul 7, 2026Holly B. KordasiewiczEVP, Chief Development OfficerSold plan362$84.30$30,517Form 4
Jul 1, 2026Joseph Klein IIIDirectorSold plan11,518$79.04$910,423Form 4
Jun 26, 2026Brett P MoniaChief Executive Officer, DirectorSold plan50,000$80.59$4.0 millionForm 4
Jun 26, 2026Eugene SchneiderEVP, Chf Clinical Develop OfcrSold plan26,000$81.05$2.1 millionForm 4
Jun 26, 2026Joseph BaroldiEVP, Chief Business OfficerSold plan5,635$80.16$451,702Form 4
Jun 26, 2026Patrick R. O'NeilEVP CLO & General CounselSold plan3,069$80.00$245,520Form 4
Jun 25, 2026Brett P MoniaChief Executive Officer, DirectorSold plan21,072$78.49$1.7 millionForm 4
Jun 25, 2026Eric SwayzeEVP ResearchSold plan10,602$79.18$839,466Form 4
The latest 12 of 71 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 92 of 93 of 9
Rule of 40−8.0%−87.9%−0.1%
Altman Z''2.221.801.12
Accruals ratio−2.1%1.6%−3.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assetsFailPassFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rosePassFailFail
Revenue rose relative to assetsPassFailPass
F-score3 of 92 of 93 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Ionis Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Ionis PharmaceuticalsFY2533.8%−40.5%−33.9%——3
Madrigal PharmaceuticalsFY25432.1%−31.3%−19.8%——3Compare
Tilray BrandsFY2611.5%−6.9%—−3.4%—3Compare
ANI PharmaceuticalsFY2543.8%12.6%19.4%15.9%0.1x6Compare
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue3475086001,123729810587788705944
Revenue growth22.2%46.5%18.1%87.2%−35.0%11.1%−27.5%34.1%−10.5%33.8%
Gross profit3475085981,118717800573778694928
Research and development340372412462531638—900902916
Operating income−2031−61366−172−30−410−354−475−382
Net income−600274278−444−29−270−366−454−381
Diluted EPS (US$)−0.500.152.071.90−3.18−0.20−1.90−2.56−3.04−2.38
Diluted shares (millions)121126134153140141142143150160
Cash flow
Cash from operations−1121746033463631−274−308−501−269
Capital expenditure7351431351216244551
Free cash flow−119139589315119−290−331−546−320
Dividends paid0000000000
Share buybacks000349000000
Acquisitions0000000000
Stock-based compensation7286131147230121100106130134
Balance sheet at fiscal year end
Cash and short-term investments6651,0232,0842,5001,8922,1151,9872,3312,2982,677
Debt incl. finance leases502535582788840—1,1941,3081,2531,812
Total assets9121,3232,6683,2332,3902,6122,5342,9903,0043,524
Total liabilities8139581,4811,5491,6461,8401,9612,6032,4153,035
Shareholders' equity1002811,0481,471743772573387588489
Margins and ratios
Gross margin100.0%100.0%99.7%99.6%98.4%98.7%97.6%98.8%98.4%98.3%
Operating margin−5.8%6.1%−10.2%32.6%−23.6%−3.7%−69.8%−44.9%−67.4%−40.5%
Net margin−17.4%0.1%45.6%24.8%−60.9%−3.5%−45.9%−46.5%−64.4%−40.4%
Free cash flow margin−34.4%27.5%98.3%28.0%0.1%2.3%−49.4%−42.1%−77.5%−33.9%
Rule of 40 (growth + FCF margin)−12.2%73.9%116.4%115.2%−34.9%13.5%−76.9%−8.0%−87.9%−0.1%
Return on capital——————————
Return on equity−40.2%0.2%41.2%22.1%−40.1%−3.8%−40.1%−76.3%−93.1%−70.8%
Return on assets−6.5%0.0%13.7%9.4%−15.8%−1.1%−10.5%−13.3%−15.2%−11.7%
Net debt to EBITDA—−12.4x—−4.5x——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Ionis Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Ionis Pharmaceuticals.